If you've noticed increased hair shedding while taking medications like Ozempic, Wegovy, or Mounjaro, you are not alone. The team at Medi Tresse specializes in diagnosing and treating GLP-1-related hair loss in women.
What Is GLP-1 Related Hair Loss?
GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have become widely used for weight management and diabetes treatment. While these medications offer significant health benefits, hair loss has emerged as a reported side effect in many patients.
The primary cause of hair shedding during GLP-1 treatment is telogen effluvium. This occurs when the body experiences stress, such as rapid weight loss, and pushes a larger percentage of hair follicles into the resting phase prematurely. Several months later, those hairs shed simultaneously, resulting in noticeable thinning.
Contributing factors may include:
- Rapid or significant weight loss
- Nutritional deficiencies in protein, iron, zinc, biotin, or vitamin D
- Reduced caloric intake affecting hair follicle nourishment
- Metabolic stress on the body
Most patients notice increased shedding approximately three to six months after beginning GLP-1 therapy, which aligns with the natural hair growth cycle. Initiating treatment for hair loss early in the weight loss journey, when possible, may help support healthier hair growth.






